NATCO Pharma Limited (NATCOPHARM.BO)
INR 771.25
(0.63%)
INR 771.25
(0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 25.96 Billion INR | 94.31% |
| 2022 | 8.05 Billion INR | 660.34% |
| 2021 | 1.05 Billion INR | -30.51% |
| 2020 | 1.52 Billion INR | -67.85% |
| 2019 | 4.74 Billion INR | -34.75% |
| 2018 | 7.26 Billion INR | -14.79% |
| 2017 | 8.52 Billion INR | 33.23% |
| 2016 | 6.4 Billion INR | 183.56% |
| 2015 | 2.25 Billion INR | 27.28% |
| 2014 | 1.77 Billion INR | 8.62% |
| 2013 | 1.63 Billion INR | 17.86% |
| 2012 | 1.38 Billion INR | 36.3% |
| 2011 | 1.01 Billion INR | 16.44% |
| 2010 | 872.81 Million INR | -6.57% |
| 2009 | 934.23 Million INR | 19.01% |
| 2008 | 785.02 Million INR | 15.65% |
| 2007 | 678.78 Million INR | 27.2% |
| 2006 | 533.65 Million INR | 7.52% |
| 2005 | 496.32 Million INR | 35.18% |
| 2004 | 367.15 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 7.6 Billion INR | 72.18% |
| 2023 Q3 | 2.6 Billion INR | -37.04% |
| 2023 Q1 | 5.35 Billion INR | 79.64% |
| 2023 Q2 | 4.14 Billion INR | -22.61% |
| 2023 Q4 | 4.41 Billion INR | 69.34% |
| 2023 FY | 15.64 Billion INR | 94.31% |
| 2022 Q3 | 644 Million INR | 20.15% |
| 2022 Q4 | 2.98 Billion INR | 362.89% |
| 2022 FY | 8.05 Billion INR | 660.34% |
| 2022 Q1 | 3.55 Billion INR | 727.34% |
| 2022 Q2 | 536 Million INR | -84.93% |
| 2021 Q4 | -567 Million INR | -186.17% |
| 2021 Q1 | 760 Million INR | 65.94% |
| 2021 FY | 1.05 Billion INR | -30.51% |
| 2021 Q2 | 358 Million INR | -52.89% |
| 2021 Q3 | 658 Million INR | 83.8% |
| 2020 Q1 | 1.61 Billion INR | 53.22% |
| 2020 Q2 | 2.73 Billion INR | 68.97% |
| 2020 Q3 | 835 Million INR | -69.46% |
| 2020 Q4 | 458 Million INR | -45.15% |
| 2020 FY | 1.52 Billion INR | -67.85% |
| 2019 Q3 | 1.34 Billion INR | -7.9% |
| 2019 FY | 4.74 Billion INR | -34.75% |
| 2019 Q4 | 1.05 Billion INR | -21.25% |
| 2019 Q2 | 1.45 Billion INR | -23.49% |
| 2019 Q1 | 1.9 Billion INR | 23.17% |
| 2018 Q4 | 1.54 Billion INR | -26.78% |
| 2018 Q3 | 2.11 Billion INR | -12.19% |
| 2018 Q2 | 2.4 Billion INR | 2.21% |
| 2018 FY | 7.26 Billion INR | -14.79% |
| 2018 Q1 | 2.35 Billion INR | -39.0% |
| 2017 FY | 8.52 Billion INR | 33.23% |
| 2017 Q1 | 1.25 Billion INR | -44.89% |
| 2017 Q4 | 3.85 Billion INR | 37.3% |
| 2017 Q2 | 1.11 Billion INR | -10.95% |
| 2017 Q3 | 2.8 Billion INR | 151.97% |
| 2016 Q4 | 2.27 Billion INR | -10.13% |
| 2016 Q1 | 693 Million INR | -14.76% |
| 2016 Q3 | 2.52 Billion INR | 169.01% |
| 2016 Q2 | 939 Million INR | 35.5% |
| 2016 FY | 6.4 Billion INR | 183.56% |
| 2015 Q4 | 813 Million INR | 53.14% |
| 2015 FY | 2.25 Billion INR | 27.28% |
| 2015 Q3 | 530.9 Million INR | 11.56% |
| 2015 Q2 | 475.9 Million INR | 2.37% |
| 2015 Q1 | 464.9 Million INR | 28.55% |
| 2014 Q4 | 361.64 Million INR | -15.35% |
| 2014 Q2 | 508.9 Million INR | 7.02% |
| 2014 Q1 | 475.5 Million INR | 28.84% |
| 2014 FY | 1.77 Billion INR | 8.62% |
| 2014 Q3 | 427.2 Million INR | -16.05% |
| 2013 Q2 | 379.9 Million INR | -7.05% |
| 2013 Q3 | 474.9 Million INR | 25.01% |
| 2013 FY | 1.63 Billion INR | 17.86% |
| 2013 Q1 | 408.7 Million INR | 45.16% |
| 2013 Q4 | 369.07 Million INR | -22.28% |
| 2012 Q1 | 263.3 Million INR | 42.45% |
| 2012 FY | 1.38 Billion INR | 36.3% |
| 2012 Q2 | 393.1 Million INR | 49.3% |
| 2012 Q4 | 281.56 Million INR | -37.19% |
| 2012 Q3 | 448.3 Million INR | 14.04% |
| 2011 Q3 | 274.2 Million INR | -0.69% |
| 2011 FY | 1.01 Billion INR | 16.44% |
| 2011 Q2 | 276.1 Million INR | 0.0% |
| 2011 Q4 | 184.83 Million INR | -32.59% |
| 2010 FY | 872.81 Million INR | -6.57% |
| 2009 FY | 934.23 Million INR | 19.01% |
| 2008 FY | 785.02 Million INR | 15.65% |
| 2007 FY | 678.78 Million INR | 27.2% |
| 2006 FY | 533.65 Million INR | 7.52% |
| 2005 FY | 496.32 Million INR | 35.18% |
| 2004 FY | 367.15 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -350.878% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 38.483% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | -189.135% |
| Granules India Limited | 6.81 Billion INR | -280.858% |
| Indoco Remedies Limited | 1.29 Billion INR | -1908.589% |
| Achyut Healthcare Limited | 4.43 Million INR | -584893.24% |
| Ajanta Pharma Limited | 19.67 Billion INR | -31.939% |
| Alkem Laboratories Limited | 19.46 Billion INR | -33.399% |
| Alpa Laboratories Limited | 184.49 Million INR | -13971.774% |
| Brooks Laboratories Limited | 14.44 Million INR | -179692.244% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -1411.616% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -2009.015% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 61.668% |
| Eris Lifesciences Limited | 5.18 Billion INR | -401.031% |
| FDC Limited | 2.98 Billion INR | -769.396% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -299.269% |
| Gufic Biosciences Limited | 1.32 Billion INR | -1852.162% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -487.302% |
| Ipca Laboratories Limited | 7.98 Billion INR | -225.314% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -5009.322% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 17185.096% |
| Lasa Supergenerics Limited | -458 Million INR | 5768.497% |
| Laurus Labs Limited | 3.94 Billion INR | -557.499% |
| Lupin Limited | 28.04 Billion INR | 7.426% |
| Mankind Pharma Limited | 21.51 Billion INR | -20.652% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -25784.347% |
| Megasoft Limited | -121.1 Million INR | 21537.772% |
| Piramal Pharma Limited | 4.55 Billion INR | -469.729% |
| RPG Life Sciences Limited | 2.29 Billion INR | -1032.574% |
| Sigachi Industries Limited | 1.47 Billion INR | -1661.454% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 75.109% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -463.455% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -10316.006% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -4457.007% |
| Windlas Biotech Limited | 1.29 Billion INR | -1898.784% |
| ZIM Laboratories Limited | 253.82 Million INR | -10128.146% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 39.773% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 730.905% |
| Divi's Laboratories Limited | 33.08 Billion INR | 21.518% |
| Hester Biosciences Limited | 364.81 Million INR | -7016.581% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -831.874% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -5574.208% |
| Bal Pharma Limited | 233.9 Million INR | -10999.188% |
| Strides Pharma Science Limited | 5.22 Billion INR | -396.803% |
| Venus Remedies Limited | 534.65 Million INR | -4755.878% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -729.956% |
| Nectar Lifesciences Limited | 923.8 Million INR | -2710.33% |
| Shilpa Medicare Limited | 1.36 Billion INR | -1800.207% |
| Aarti Drugs Limited | 7.14 Billion INR | -263.17% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -1525.877% |
| Suven Life Sciences Limited | -1.22 Billion INR | 2217.926% |
| Ind-Swift Limited | 1.22 Billion INR | -2017.68% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | -81.771% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 773.83% |
| Themis Medicare Limited | 392.58 Million INR | -6513.023% |
| Hikal Limited | 32.11 Million INR | -80753.317% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | -2.474% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -4043.974% |
| Wockhardt Limited | -670 Million INR | 3974.925% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -400.328% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -286181.385% |
| Neuland Laboratories Limited | 5.31 Billion INR | -388.183% |
| Morepen Laboratories Limited | 4.17 Billion INR | -522.018% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -12378.731% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -94451.679% |